These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33610374)

  • 1. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
    Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
    Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
    Sanchez L; Matsuoka O; Inoue S; Inoue T; Meng Y; Nakama T; Kato K; Pandey A; Chang LJ
    Hum Vaccin Immunother; 2020 Apr; 16(4):858-866. PubMed ID: 31634025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.
    Fan R; Huang X; Nian X; Ou Z; Zhou J; Zhang J; Zeng P; Zhao W; Deng J; Chen W; Chen S; Duan K; Chen Y; Li X; Zhang J; Yang X
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-9. PubMed ID: 34473607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
    Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
    Chu K; Xu K; Tang R; Tian X; Hu J; Yang T; Li C; Hu Y; Zeng G
    Vaccine; 2020 Aug; 38(37):5940-5946. PubMed ID: 32732142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S; Nicolas JF; Szymanski H; Leroux-Roels I; Schaum T; Bonten M; Icardi G; Shrestha A; Tabar C;
    Hum Vaccin Immunother; 2021 Dec; 17(12):5475-5486. PubMed ID: 34714720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M; Tarigan R; Fadlyana E; Prasetyo D; Amalia N; Rusmil VK; Sari RM; Bachtiar NS; Rusmil K; Kartasasmita CB
    Vaccine; 2020 Jan; 38(5):993-1000. PubMed ID: 31862195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
    Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
    Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.
    Dawood FS; Naleway AL; Flannery B; Levine MZ; Murthy K; Sambhara S; Gangappa S; Edwards L; Ball S; Grant L; Belongia E; Bounds K; Cao W; Gross FL; Groom H; Fry AM; Rentz Hunt D; Jeddy Z; Mishina M; Kim SS; Wesley MG; Spencer S; Thompson MG; Gaglani M
    Clin Infect Dis; 2021 Dec; 73(11):1973-1981. PubMed ID: 34245243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
    Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP; Robertson CA; Talbot HK; Decker MD
    Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.